FDA GLP-1 drug safety warnings 2026
One page that accretes the verified record as the story develops. Every fact keeps its date and its sources.
FDA warns of vision loss risk linked to GLP-1 weight-loss drugs
Semaglutide is the active ingredient in Wegovy and Ozempic.
Eli Lilly is the company behind Mounjaro, Zepbound and Foundayo.
Studies have shown that semaglutide and tirzepatide cause thyroid C-cell tumors in rodents.
FDA orders new warning on GLP-1 drugs for rare eye condition linked to blindness
The FDA found a NAION incidence rate of 6.4 cases per 100,000 person-years among GLP-1 patients, compared to 3.8 cases among patients on placebo or alternative glucose-lowering medications.
The FDA reviewed 126 clinical trials involving over 134,200 patients and identified 15 probable NAION cases, including 10 among GLP-1 patients and 5 among patients receiving placebo.
Novo Nordisk said the data do not establish a cause-and-effect relationship between GLP-1 drugs and NAION.